Selenium-Binding Protein 1 Deficiency Inhibits the Antitumor Immunity of Dendritic Cells
Shuang Han, Yi Li, Jie Meng, Jie Dai, Zhu Zeng, Yi JiaAims:
Selenium-binding protein 1 (SELENBP1) correlates positively with the prognosis of patients with colitis and colon cancer. SELENBP1-deficient dendritic cells (DCs) promote regulatory T cell differentiation and exert direct immunomodulatory functions. This study aimed to investigate whether SELENBP1-deficient DCs mediate antitumor immune function by affecting CD8 + T cell activation or exhaustion.
Results:
Our findings revealed that SELENBP1 deficiency in mice accelerates colon cancer progression, characterized by reduced numbers of activated DCs and cytotoxic CD8
+
T cells, increased intratumoral exhaustion-related factors, and impaired CD8
+
T cell tumor-killing capacity. Adoptive-transfer experiments showed that SELENBP1 deficiency impairs DC antitumor activity, which may be associated with decreased intratumoral DCs, reduced cytotoxic CD8
+
T cells, and increased dysfunctional T cell phenotypes. Moreover,
Innovation:
This study is the first to investigate the antitumor immune function of SELENBP1 in DCs.
Conclusion: